STIM Neuronetics, Inc.
FY2025 10-K
Neuronetics, Inc. (STIM) filed its fiscal year 2025 10-K annual report with the SEC on Mar 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development and commercialization of NeuroStar Advanced Therapy System, a non-invasive TMS treatment for MDD and OCD, plus operation of Greenbrook mental health treatment centers
- • New emphasis on fully integrated care via Greenbrook acquisition, adding 93 clinics and SPRAVATO treatment for treatment-resistant depression
Management Discussion & Analysis
- • Revenue $149.2M in 2025, up 99% YoY from $74.9M in 2024; U.S. revenue $146.0M up 101% YoY; international $3.1M up 29% YoY
- • Gross margin 48.5% in 2025 vs 72.3% in 2024, decline due to Greenbrook clinic business inclusion and reduced treatment session revenue
Risk Factors
- • Cybersecurity risk oversight by board Audit Committee with quarterly enterprise risk profile reports from Head of IT
- • Head of IT with 20+ years experience leads cybersecurity program and partners with third-party experts for risk identification
Financial SummaryXBRL
Revenue
$149M
Net Income
-$39M
Gross Margin
48.5%
Operating Margin
-21.1%
Net Margin
-26.1%
ROE
-174.3%
Total Assets
$142M
EPS (Diluted)
$-0.59
Operating Cash Flow
-$20M
Source: XBRL data from Neuronetics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Neuronetics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.